New Products Soar And Old Stand Their Ground As Roche Heads Off Biosimilar Threat
Executive Summary
New products helped Roche to 7% sales growth in 2018 but the outlook for 2019 is lower as the biosimilar headwinds start to blow from the US.
You may also be interested in...
EU's CHMP OKs Major New Uses for Hemlibra, Praluent, Forxiga – And More
Several major products have been recommended for wider indications in the EU, including Roche’s hemophilia drug Hemlibra, Sanofi’s Praluent in atherosclerotic disease, and AstraZeneca’s Forxiga for type 1 diabetes.
Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.